Baseline renal function screening

被引:90
作者
Lameire, Norbert
Adam, Andy
Becker, Christoph R.
Davidson, Charles
McCullough, Peter A.
Stacul, Fulvio
Tumlin, James
机构
[1] Univ Hosp, Dept Med, B-9000 Ghent, Belgium
[2] St Thomas Hosp, Dept Radiol, London SE1 7EH, England
[3] Univ Hosp Grosshadern, Dept Clin Radiol, Munich, Germany
[4] NW Mem Hosp, Dept Med, Chicago, IL 60611 USA
[5] William Beaumont Hosp, Royal Oak, MI 48072 USA
[6] Univ Trieste, Dept Radiol, Trieste, Italy
[7] SERRI, Charlotte, NC USA
关键词
D O I
10.1016/j.amjcard.2006.01.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal impairment at baseline (estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m(2)) is the most important risk marker to predict the risk of contrast-induced nephropathy (CIN) in patients receiving iodinated contrast media. Hence, it is important to assess renal function before administration of contrast medium to ensure that appropriate steps are taken to reduce the risk. Serum creatinine alone does not provide a reliable measure of renal function, hence the National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) recommends that clinicians should use an eGFR calculated from the serum creatinine as an index of renal function. The CIN Consensus Working Panel agreed that eGFR should be determined before contrast administration, using the abbreviated Modification of Diet in Renal Disease (MDRD) formula, recommended by K/DOQI as the preferred equation for the calculation of eGFR in adults. Where a serum creatinine measurement or eGFR is not available, a simple survey or questionnaire can be. used before contrast agent administration to identify patients at higher risk for CIN, compared with the general, population. In emergency situations, where the benefit of very early imaging outweighs the risk of waiting, the CIN Consensus Working Panel agreed that the procedure can be performed without assessment of renal function. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:21K / 26K
页数:6
相关论文
共 26 条
[1]   Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis [J].
Bagshaw, Sean M. ;
Ghali, William A. .
BMC MEDICINE, 2004, 2 (1)
[2]  
BARRETT BJ, 1994, J AM SOC NEPHROL, V5, P125
[3]   NEPHROTOXICITY OF CONTRAST-MEDIA [J].
BERNS, AS ;
KANTER, A ;
COHEN, JJ ;
GARELLA, S ;
SIMON, N ;
DUFFY, B ;
SPRAGUE, S ;
LAU, K .
KIDNEY INTERNATIONAL, 1989, 36 (04) :730-740
[4]  
Choyke P L, 1998, Tech Urol, V4, P65
[5]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]   Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate [J].
Coresh, J ;
Astor, BC ;
McQuillan, G ;
Kusek, J ;
Greene, T ;
Van Lente, F ;
Levey, AS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (05) :920-929
[7]   Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration [J].
Coresh, J ;
Eknoyan, G ;
Levey, AS .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (11) :2811-2812
[8]   CARDIOVASCULAR AND RENAL TOXICITY OF A NONIONIC RADIOGRAPHIC CONTRAST AGENT AFTER CARDIAC-CATHETERIZATION - A PROSPECTIVE TRIAL [J].
DAVIDSON, CJ ;
HLATKY, M ;
MORRIS, KG ;
PIEPER, K ;
SKELTON, TN ;
SCHWAB, SJ ;
BASHORE, TM .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (02) :119-124
[9]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[10]  
Glauser Jonathan, 2004, Emerg Radiol, V10, P319